DrugDashboards

Sodium Chloride

Sodium Chloride · SODIUM CHLORIDE 4.5 g/1000mL · Injection, Solution · Intravenous · Baxter Healthcare Corporation

NDC 00338-0043-04 · 1000 mL in 1 BAG · NDA · View full market →

The short version

20 companies supply this market — deep enough that no single failure threatens the supply. One of its named manufacturing plants, Baxter Healthcare Corporation, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Historically, drugs in this position went on to a new shortage within 90 days about 1.5% of the time — roughly 10× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Part D plans paid (avg)$0.1274per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$0.0105per unitnegotiated price across 5,496 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$25.62per package of 14X1000MLBaxter Healthcare Corporation · Sep 17, 2025

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.0105per unit
middle half $0.0070$0.0374 · 5,496 plans · Apr 1, 2026
Est. net of rebates
$0.0063–$0.0079
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$6.26
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$105,315
4,766 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

1.5%chance of a new FDA shortage posting for sodium chloride (injectable) in the next 90 days

sterile injectable · 13 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 10× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 3 across plans
  • Costs ≥ $950/fill · avg $16.68 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA018016
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67)Dec 3, 2025
  • Planned discontinuation Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02)Dec 3, 2025

Recalls (this NDC)

  • Class II · TerminatedJul 18, 2019
    Baxter Healthcare CorporationLack of Assurance of Sterility: Bags have potential to leak.
  • Class II · TerminatedSep 6, 2018
    Baxter Healthcare CorporationcGMP Deviation
  • Class II · TerminatedAug 21, 2018
    Baxter Healthcare CorporationCGMP Deviations
  • Class II · TerminatedJul 6, 2017
    Baxter Healthcare CorporationLack of Assurance of Sterility: Customer complaints for leaking bags.
  • Class II · TerminatedJul 6, 2017
    Baxter Healthcare CorporationLack of Assurance of Sterility: Bags have the potential to leak.
  • Class I · TerminatedDec 15, 2015
    Baxter Healthcare Corp.Presence of Particulate Matter: Confirmed customer compliants of finding an insect floating in the primary container of each product.
  • Class II · TerminatedSep 2, 2015
    Baxter Healthcare CorporationLack of Assurance of Sterility: Recalling firm reported a complaint for mold on the interior surface of the overpouch.
  • Class I · TerminatedJul 17, 2015
    Baxter Healthcare Corp.Presence of Particulate Matter: Customer complaint for an insect found free floating inside a single bag for each lot recalled.
  • Class II · TerminatedJul 2, 2015
    Baxter Healthcare Corp.Presence of Particulate Matter and Lack of Assurance of Sterility: The firm received a complaint for customer of presence of particulate matter, leaky containers, and missing port protectors.
  • Class I · TerminatedMar 24, 2015
    Baxter Healthcare Corp.Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal)
  • Class II · TerminatedMar 23, 2015
    Baxter Healthcare CorpLack of Assurance of Sterility; increased complaints received for leaks
  • Class II · TerminatedMar 18, 2015
    Baxter Healthcare Corp.Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which may compromise product sterility.
  • Class II · TerminatedJul 30, 2014
    Baxter Healthcare Corp.Lack of Assurance of Sterility; complaints of mold in the overpouch
  • Class I · TerminatedJul 11, 2014
    Baxter Healthcare Corp.Presence of Particulate Matter: particulate matter identified as fibers and/or plastics.
  • Class I · TerminatedNov 21, 2013
    Baxter Healthcare Corp.Presence of Particulate Matter: Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag
  • Class II · TerminatedMay 21, 2013
    Baxter Healthcare Corp.Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.

Manufacturers of Sodium Chloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
B. Braun Medical Inc.SODIUM CHLORIDE .9 g/100mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE .9 g/100mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 450 mg/100mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 3, 2026
ICU Medical Inc.SODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 3, 2026
Spectra Medical Deviecs, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 3, 2026
Asclemed USA, Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
B. Braun Medical Inc.SODIUM CHLORIDE 3 g/100mLJul 15, 2026Sep 2, 2026
B. Braun Medical Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
B. Braun Medical Inc.SODIUM CHLORIDE 5 g/100mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 5 g/100mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 3 g/100mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 4.5 g/1000mLJul 15, 2026Sep 2, 2026
Becton Dickinson and CompanySODIUM CHLORIDE .9 g/100mLJul 15, 2026Sep 2, 2026
Becton Dickinson and CompanySODIUM CHLORIDE 450 mg/100mLJul 15, 2026Sep 2, 2026
Becton Dickinson and CompanySODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Becton Dickinson And CompanySODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Codan Us CorporationSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 2250 mg/500mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 234 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 3 g/100mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 225 mg/50mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 1125 mg/250mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstSODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 2, 2026
Hospira, Inc.SODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 2, 2026
Laboratorios Grifols SaSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
Medefil, Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Nextgen Pharmaceuticals LLCSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
ProPharma DistributionSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
SOLA Pharmaceuticals, LLCSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
Sportpharm LLCSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 9 g/1000mLJul 15, 2026Aug 31, 2026
ICU Medical Inc.SODIUM CHLORIDE 450 mg/100mLJul 15, 2026Aug 31, 2026
ProPharma DistributionSODIUM CHLORIDE 9 mg/mLJul 15, 2026Aug 31, 2026
Henry Schein, Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Aug 29, 2026
B. Braun Medical Inc.SODIUM CHLORIDE .45 g/100mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sodium Chloride — NDC 00338-0043-04," retrieved September 3, 2026, https://drugdashboards.com/drug/00338004304.

Free to cite with attribution — see how the data is put together.